Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Net Income towards Common Stockholders (2016 - 2026)

Ocular Therapeutix has reported Net Income towards Common Stockholders over the past 14 years, most recently at -$90.1 million for Q1 2026.

  • For Q1 2026, Net Income towards Common Stockholders fell 42.79% year-over-year to -$90.1 million; the TTM value through Mar 2026 reached -$290.5 million, down 47.9%, while the annual FY2025 figure was -$263.5 million, 59.62% down from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 was -$90.1 million at Ocular Therapeutix, down from -$65.2 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at -$19.5 million in Q1 2022 and troughed at -$90.1 million in Q1 2026.
  • A 5-year average of -$40.8 million and a median of -$31.7 million in 2024 define the central range for Net Income towards Common Stockholders.
  • Biggest five-year swings in Net Income towards Common Stockholders: grew 10.95% in 2022 and later crashed 115.51% in 2024.
  • Year by year, Net Income towards Common Stockholders stood at -$20.8 million in 2022, then decreased by 9.42% to -$22.7 million in 2023, then crashed by 115.51% to -$49.0 million in 2024, then plummeted by 33.13% to -$65.2 million in 2025, then tumbled by 38.04% to -$90.1 million in 2026.
  • Business Quant data shows Net Income towards Common Stockholders for OCUL at -$90.1 million in Q1 2026, -$65.2 million in Q4 2025, and -$68.0 million in Q3 2025.